Grand Rounds – The Concept of Innovation and Orchestration: Translating Therapies from Bench to Bedside | Kahlid Shah, MS PhD | Jan 18, 2023

Dr. Shah and his team have pioneered major developments in translational cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic cells for cancer. These studies have been published in a number of very high impact journals. Previously, Dr. Shah’s translational stem cell work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Recently, Dr. Shah’s laboratory has reverse engineered cancer cells using CRISPR/Cas9 technology and utilized them as therapeutics to treat cancer. This work was published in journal Science Translation Medicine and highlighted world-wide including features on Boston Herald, Sky News and Scientific American. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of cell therapy and oncology. In an effort to translate the exciting therapies developed in his laboratory into clinics, he has founded two biotech companies whose main objective is the clinical translation of therapeutic cells in cancer patients. A prolific innovator, published researcher and author, Dr. Shah is keen to bridge integrate different scientific disciplines to ultimately find a cure for cancer.

Learn More: www.innovationmeshnetwork.org / innovation.massgeneralbrigham.org

Chief Innovation Officer: Chris Coburn
Grand Rounds Director: Marc Succi, MD